Anthera Pharmaceuticals, Inc. (ANTH)
| Market Cap | 2,618 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.93M |
| Shares Out | 26.18M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,000 |
| Open | 0.0400 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | 0.0001 - 0.1890 |
| Beta | 1.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ANTH
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ...
Financial Performance
Financial StatementsNews
AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which to...
AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Annou...
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged following...